Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Andrew Turner suffers from ankylosing spondylitis, a form of spinal arthritis that often spreads to other joints, which also affects about one in 200 Canadians.

The Globe and Mail

An article in Thursday's Globe raised eyebrows about whether it was a balanced depiction of a drug treatment. The first issue was the headline, which said in print: From bedridden to Ironman, via a medical miracle. Online, the initial headline said: From bedridden to Ironman: thanks to a miracle medicine. It has since been changed to remove the word "miracle" and say: one man's journey with spinal arthritis.

Kathryn Hayward, acting editor of Life and Arts (which includes the Health page) said the print headline referred "to one man's miraculous change from being immobile to training for the Ironman. We aren't saying it's a miracle cure. We're saying his recovery is remarkable. It's unfortunate if it's deemed misleading. We never want to give false hope to patients."

I would say that both headlines (print and the initial online) were a step too far. While the man profiled in the story has seen his health improve remarkably, the term "miracle" was hyperbole.

Story continues below advertisement

Questions were raised by Gary Schwitzer, the publisher of HealthNewsReview.org, a group that reviews news stories. I agree with Mr. Schwitzer that the article could have been more balanced. The Globe article properly included the synopsis of the study into the new treatment of spinal arthritis in the medical journal Arthritis and Rheumatism, which said that patients on TNF-inhibitors were much less likely to deteriorate than those taking other medicines. But the article failed to include a more skeptical view expressed in the same journal, which said the results of this study should be interpreted with caution.

The Globe article also did not refer to side effects or the cost of the drug.

Michael Posner, The Globe article's author, said he understands the cost is in the thousands, but many provincial drug plans cover it (although only for specific indications).

On the question of the more skeptical view expressed in an editorial in the journal, Mr. Posner said he would be careful not to rush to judgment. "There are competing views and the details are highly complex."

I have no doubt of the complexity and I am not an expert in medical research and would be in no position to assess such work. I think that is all the more reason why readers should be told of competing views and given all the information so they can know whether to raise the possibility of medical treatments or medications with their own doctors.

On Mr. Schwitzer's final point in his blog about an ad from a drug company running adjacent to the article, that ad is not on The Globe's homepage, but it was attached to his version of the story, likely through a search term.

Readers can contact me at publiceditor@globeandmail.com

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies